Background. Little is known about the epidemiology of perianal infection in pediatric cancer patients. Objectives were to describe the characteristics, treatment and outcome of perianal infection and describe features of those with and without definite abscess in pediatric patients with acute myeloid leukemia (AML).
Methods. We performed a retrospective analysis of two multi-center cohort studies investigating risk factors for infection in children with AML. We included children with de novo AML ≤18 years of age with a perianal infections prior to the completion of AML treatment or stem cell transplantation
Results. Of 235 patients with AML, 17 (7%) experienced 19 perianal infections. Median age at perianal infection was 8.2 (range 0.6-16.1) years. Local bacterial cultures were positive in 6 (32%) episodes, but none matched bacteremia isolates (n = 5). Enterobacteriacae were the most common pathogen. The 19 episodes were stratified by definite abscess (n = 12) and cellulitis/phlegmon (n = 7). All patients presented with local pain, erythema and induration or swelling. Fever was a frequent finding (n = 17, 89.4%). Among the patients with abscess, 9 (75%) were severely neutropenic at diagnosis and surgical intervention was required in 8 (42%). All patients received antibiotics; Metronidazole (n = 14) and Piperacillin/Tazobactam (n = 10) were the drugs most frequently used for treatment. Imaging was commonly performed (n = 16). Diagnostic yield was similar between computerized tomography of pelvis (5/10) and ultrasound (3/5). Severe complications occurred including fistula (n = 1), skin necrosis (n = 2) and mortality (n = 1).
Conclusion. Perianal infections occurred in 7% of pediatric patients with AML, with many consisting of definite abscess. Diagnostic yield were similar regardless of imaging modality and therefore, ultrasound may be considered for initial evaluation. Future research should develop consistent management approaches to perianal infection in order to improve outcomes.
Disclosures. All authors: No reported disclosures. Background. Hematopoietic cell transplant (HCT) recipients are at a significantly greater risk for invasive pneumococcal disease than the general population. However, pneumococcal colonization in pediatric HCT recipients has not been widely studied. We evaluated the dynamics of pneumococcal colonization in pediatric patients undergoing HSCT from conditioning regimen to 100 days post HCT.
Pneumococcal Colonization in Pediatric Patients
Methods. Mid-turbinate samples obtained from pediatric patients undergoing HCT at Children's Mercy from September 2015 to January 2017 were tested for Streptococcus pneumoniae colonization via real-time PCR using lytA primer (autolysin-A-encoding gene). A cycle threshold value ≤35 was considered positive. First sample was obtained during conditioning regimen (week 1), second sample after HCT (week 2). Then, weekly samples were obtained for the first 100 days after HSCT.
Results. Twenty-two patients were included, representing 266 mid-turbinate samples. The median age at the time of HSCT was 9.5 years (IQR 3-16), and 14 patients were male (63.6%). The indication for HSCT was oncologic (15, 68.2%), hematologic (5, 22.7%) and immune deficiency (2, 9.1%). Fourteen patients (63.6%) underwent allogenic HSCT. Six patients had documentation in our electronic medical record system of receiving ≥ 1 pneumococcal conjugate vaccine prior to conditioning regimen. Nine (40.9%) of 22 patients were colonized with S. pneumoniae, their median age was 14 years (IQR 2.5-16). Pneumococcal colonization during conditioning regimen was 9% (2/22). Pneumococcal colonization from week 14 to week 16 was 42% (5/12).
Conclusion. A third of pediatric HCT recipients were colonized with S. pneumoniae. Pneumococcal colonization was mainly identified either at the time of conditioning regimen or toward the end of the first 100 days after HCT, with the latter being the most common. Background. An increase in human adenovirus (HAdV) infections among hospitalized children in Singapore was observed since 2013. Cidofovir is often used to treat severe HAdV infections despite limited data. This study describes the epidemiology and outcomes of children with severe HAdV disease requiring high dependency (HD) or intensive care unit (ICU) admission in our hospital (KKH).
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Trends in Adenovirus Infections in Singapore Children and Outcomes of Cidofovir Treatment in the Severely Ill
Methods. This is a retrospective cohort study of HAdV-infected children admitted to HD and ICU in KKH from January 2013 to September 2017. Characteristics and outcomes of those who received IV cidofovir was also reviewed.
Results. HAdV admissions and genotype profiles in KKH are described in Figures 1 and 2 , respectively. There were 85 children with severe HAdV infection, of which 17 (20%) received cidofovir for mainly viremia (8, 47.1%) and pneumonia (7, 41.2%) . Of these 17 patients, 7 (41.2%) died. More children treated with cidofovir had genotype 7 infection (8 of 17, 47.1%) vs. 13 of 68 (19.1%) who did not (P = 0.027). Characteristics of patients who received cidofovir are described in Table 1 . None experienced adverse reactions from cidofovir. All are n (%) unless stated otherwise.
Conclusion.
More children with HAdV genotype 7 infection required cidofovir treatment. HAdV pneumonia and ICU admission are potential risk factors for mortality despite cidofovir treatment.
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